CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

Rhea-AI Summary

CytoMed Therapeutics Limited, a Singapore biopharmaceutical company, has been granted a patent by the China National Intellectual Property Administration for its induced pluripotent stem cell (iPSC)-based technology. The patent covers the tech to derive synthetic γδ NKT cells for cancer treatment. CytoMed can generate novel types of synthetic hybrid immune cells without genetic modification or viral vectors, making it a potential 'off-the-shelf' cell therapy. The company also holds patents in the US and China for its licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology.

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced its exclusively licensed induced pluripotent stem call (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

"We're thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based technology has been granted patent in China and Japan (where the iPSC technology was pioneered in 2006). Such progress further expands the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology which is expected to start phase I clinical trial in Singapore soon."

The granted patent is titled "Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells" under Patent No. ZL201880022790.X, published as CN 110691844 B. CytoMed's new patent specifically covers tech to derive novel synthetic γδ NKT cells for the treatment of a wide range of cancers, such as hematological malignancies and solid tumors.

Immune cells like γδ NKT cells and natural killer (NK) cells are extremely valuable as a viable cancer treatment due to their ability to express an array of built-in receptors that can naturally recognize stress-induced cancer antigens.

Using the patented iPSC technology, CytoMed can generate novel types of synthetic hybrid immune cells, γδ NKT cells, which can express receptors of both γδ T cells and NK cells without the use of genetic modification or viral vectors. As a result, the company can use this as an allogeneic cell source to become a potential "off-the-shelf" cell therapy capable of helping a large number of cancer patients.

The assets continue its preclinical development and CytoMed maintains an exclusive, worldwide license to use this patented technology as stated under its previously disclosed licensing agreement from June 1, 2018.

For more information about the company's services, latest news, and ongoing initiatives, visit https://w2.cytomed.sg and https://spotlightgrowth.com/singapores-journey-to-becoming-a-biotech-powerhouse/

About CytoMed Therapeutics Limited

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology, and Research (A*STAR), Singapore's national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. For more information about CytoMed, please visit www.cytomed.sg.

About Spotlight Growth

SpotlightGrowth.com is a digital hub for micro-caps, small-caps, venture capital, private equity, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small-cap companies. Follow us on social media: Twitter; Facebook; Instagram; Reddit; and YouTube.

Disclaimer

This communication was produced by Spotlight Growth (SG), an IR advisor to small and micro-cap companies. SG is not a registered or licensed broker-dealer or investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. SG may be compensated by respective clients for publicizing information relating to its client's securities. See https://spotlightgrowth.com/disclosures for more information.

Contact:

CytoMed Therapeutics
enquiry@cytomed.sg

Spotlight Growth
info@spotlightgrowth.com

SOURCE: CytoMed Therapeutics Limited

View source version on accesswire.com:
https://www.accesswire.com/796022/cytomed-therapeutics-adds-to-its-intellectual-portfolio-after-securing-chinese-patent-for-its-licensed-ipsc-based-technology

FAQ

What is the company that has been granted the patent for iPSC-based technology?

The company that has been granted the patent for iPSC-based technology is CytoMed Therapeutics Limited.

What does the patent cover?

The patent covers the technology to derive synthetic γδ NKT cells for the treatment of various cancers.

How does CytoMed generate synthetic hybrid immune cells?

CytoMed can generate synthetic hybrid immune cells, γδ NKT cells, without genetic modification or viral vectors using its patented iPSC technology.

What is the potential of the patented technology?

The patented technology has the potential to be an 'off-the-shelf' cell therapy that can help a large number of cancer patients.

What other patents does CytoMed hold?

CytoMed also holds patents in the US and China for its licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology.